Introduction {#sec1}
============

Methicillin-resistant *Staphylococcus aureus* (MRSA) is recognized as one of the most common pathogens of both nosocomial and community-acquired infections worldwide. As a feature distinct from methicillin-susceptible *S. aureus* (MSSA), MRSA has a transmissible genome element, staphylococcal cassette chromosome *mec* (SCC*mec*), inserted in a specific site of the chromosome. The SCC*mec* in MRSA has been differentiated into at least 12 genetic types (I--XII) [@bib1], [@bib2], among which types I--III have been traditionally associated with hospital-acquired MRSA (HA-MRSA), while type IV and V have been commonly found in community-acquired MRSA (CA-MRSA) [@bib3]. However, in recent years, CA-MRSA with the dominant SCC*mec* types (IV and V) has been brought to healthcare settings causing nosocomial infections [@bib4], [@bib5], [@bib6], which makes distinction between HA- and CA-MRSA more difficult in terms of SCC*mec* type. The pathogenesis of many CA-MRSA strains have been attributed to the production of Panton-Valentine leukocidin (PVL), a two-component toxin encoded by two genes, *lukF-PV* and *luk-S-PV,* which are carried on lysogenic bacteriophages [@bib7], [@bib8]. The PVL causes leukocyte lysis or apoptosis *via* pore formation [@bib9]. Accordingly, PVL-positive *S. aureus* is associated with severe symptoms in a wide spectrum of infections including skin and soft tissue infections and necrotizing pneumonia [@bib10], [@bib11]. Prevalence of CA-MRSA harbouring PVL genes has been increasing recently in hospitalized patients as well as healthy individuals in the community [@bib12], [@bib13].

Distribution and spread of MRSA clones on a global scale have been revealed by genetic classifications with multilocus sequence typing and SCC*mec* typing [@bib14], [@bib15]. Several HA-MRSA clones including ST5-MRSA-SCC*mec* II (ST5-II, NY/Japan clone) and ST22-IV (EMRSA-15) are known as pandemic clones predominating in East Asia/North America and Europe, respectively. In contrast, various clones have been documented for CA-MRSA which are distributed locally or predominate in a region, often associated with international spread. Globally predominant CA-MRSA includes five clones, i.e. ST1 (USA400 clone), ST8 (USA300 clone), ST30 (South West Pacific clone), ST59 (Taiwan clone) and ST80 (European clone), among which ST8 and ST30 are considered pandemic as a result of its distribution to every continent [@bib15]. In Asia, two pandemic HA-MRSA clones with ST5 and ST239 are disseminating, whereas various CA-MRSA clones including those with ST8, ST30, ST59, ST72 and ST772 have been reported [@bib16].

In Nepal, the prevalence of MRSA from clinical specimens in hospitals has been described to be 26--69% in several studies *via* antimicrobial susceptibility testing [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], although the rate varies depending on the types of infections or specimens examined. A recent study revealed a high prevalence of PVL genes in nosocomial isolates of MRSA and MSSA (26% and 52% respectively) [@bib22]. However, in Nepal, there have been no studies conducted on genotypes (ST and SCC*mec* types) of clinical MRSA isolates, particularly PVL-positive isolates.

We analysed recent clinical isolates of MRSA and MSSA in hospitals in Nepal. We found high prevalence of PVL in MRSA and MSSA, as well as the presence of PVL-positive ST772 MRSA-V (Bengal Bay clone). A deletion variant of elastin binding protein gene was first identified in ST22 *S. aureus* isolates and its origin was analysed.

Materials and Methods {#sec2}
=====================

Bacterial isolates and initial genetic analysis {#sec2.1}
-----------------------------------------------

From August 2012 to October 2012, about 200 *S. aureus* isolates were collected from two general hospitals (approximately 100 isolates each) with more than 500 beds in Kathmandu, Nepal. These isolates were transported to Genesis Laboratory and Research and processed. Of these, only 100 isolates recovered were included in this study. The main specimen of the isolates was pus (*n* = 84), followed by urine (*n* = 12), sputum and blood (*n* = 2 each). A single isolate from each individual patient was subjected to study. Bacterial isolation and species identification were performed by conventional microbiological methods, and the presence of nuclease gene was confirmed by multiplex PCR. Individual bacterial strains were stored in Microbank (Pro-Lab Diagnostics, Richmond Hill, ON, Canada) at −80°C and recovered when they were analysed.

Staphylococcal 16s rRNA, *nuc, mecA,* PVL gene (*lukS-PV*/*lukF-PV*) and ACME-*arcA* (arginine deiminase gene) were detected for all isolates by multiplex PCR assay as described by Zhang *et al*. [@bib23]. SCC*mec* type was determined by multiplex PCR using previously published primers and conditions [@bib24].

Antimicrobial susceptibility testing and detection of drug resistance genes {#sec2.2}
---------------------------------------------------------------------------

Minimum inhibitory concentrations against 18 antimicrobial agents based on the broth microdilution test were measured by using Dry Plate 'Eiken' DP32 (Eiken Chemical, Tokyo, Japan). Breakpoints defined in the Clinical Laboratory Standards Institute guidelines were used to distinguish between resistant and susceptible strains for most of drugs examined [@bib25]. Antimicrobial resistance genes were detected by multiplex or uniplex PCR using primers described previously [@bib26].

Genetic typing, detection and analysis of virulence factors {#sec2.3}
-----------------------------------------------------------

Staphylocoagulase genotype (*coa* type) of *S. aureus* isolates was determined by multiplex PCR using previously published primers and conditions [@bib27]. For the strains for which the *coa* types were not determined for I--X by the multiplex PCR, partial *coa* sequences (D1, D2 and the central regions) were determined as described previously [@bib28], [@bib29] to assign the *coa* genotype by sequence identity via BLAST search (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). For selected isolates, sequence type (ST) was determined according to the scheme of multilocus sequence typing [@bib30], and *agr* group was classified as described previously [@bib31].

Presence of genes encoding enterotoxins and other toxins, adhesins, other proteins related to virulence and antimicrobial resistance genes was analysed by multiplex or uniplex PCR using primers described previously [@bib26], [@bib32]. The sequence of the gene encoding elastin binding protein (*ebpS*) was determined by PCR and direct sequencing, as described previously [@bib26]. Multiple alignment of *ebpS* sequences determined in the present study and those retrieved from the GenBank database was performed by the MultAlin interface (<http://multalin.toulouse.inra.fr/multalin/>). The LALIGN program (European Bioinformatics Institute; <http://www.ebi.ac.uk/Tools/psa/lalign/nucleotide.html>) was used for pairwise alignment and calculation of identity between two *ebpS* sequences. A phylogenetic tree of *ebpS* was constructed by the neighbour-joining method by MEGA 5.01 software, statistically supported by bootstrapping with 1000 replicates.

Full-length *ebpS* sequences of strains NP173, NP177 and NP199 determined in the present study were deposited in the GenBank database under accession numbers KT951674--KT951676 respectively.

Results and Discussion {#sec3}
======================

Among the 100 *S. aureus* clinical isolates examined, 32 isolates were MRSA which had SCC*mec* type V (*n* = 20, 62.5%) or type IV (*n* = 2, 6.3%) ([Table 1](#tbl1){ref-type="table"}), while SCC*mec* type was not identified for ten isolates. PVL genes were detected in 78% (25/32) of MRSA and 71% (48/68) of MSSA isolates. The most common coagulase genotypes of PVL-positive MSSA and MRSA were IVa and VIa, respectively. Genetic characteristics were analysed for 17 isolates as representatives of PVL-positive MRSA (seven isolates), PVL-positive MSSA (six isolates), PVL-negative MRSA (three isolates) and a PVL-negative MSSA isolate ([Table 2](#tbl2){ref-type="table"}). The PVL-positive MRSA isolates belonged to ST1, ST22, ST88 or ST772. The ST772 was identified into MRSA with SCC*mec* V, *coa*-VIa and *agr*-II (one PVL-negative and four PVL-positive isolates), as well as two PVL-positive MSSA. ST22 was also identified in *mecA*-positive and/or PVL-positive isolates. MRSA isolates with or without PVL were mostly resistant to ampicillin, gentamicin and levofloxacin, and had generally more drug resistance genes than PVL-positive MSSA, although some *mecA*-positive isolates (MRSA) were susceptible to oxacillin ([Supplementary Table S1](#appsec1){ref-type="sec"}). Although *lukE-lukD* and haemolysin genes were detected in most isolates examined, ST772 isolates (MRSA and MSSA) and ST22 MRSA had more enterotoxin genes than ST1 and ST88 MRSA and ST30 MSSA isolates ([Table 2](#tbl2){ref-type="table"}).

In the present study, we first demonstrated the presence of ST772-MRSA-V and ST22-MRSA-IV in Nepal. ST772 and ST22 have been reported as epidemic clones associated with infections in both community and healthcare settings in India [@bib16], [@bib33], [@bib34], [@bib35]. ST772 MSSA was originally reported in Bangladesh [@bib36]; thereafter, ST772-MRSA-V was identified in India, followed by transmission to East/Southeast Asia, Australia, New Zealand, the Middle East and Europe [@bib15]. This clone is colloquially referred to as the Bengal Bay clone, and it is mostly PVL positive and relatively multiresistant compared to other CA-MRSA [@bib37]. In addition to the increasing prevalence of ST772-MRSA-V in India, detection of this clone outside India has been related to travel history to or from India [@bib14], [@bib37], [@bib38]. Because of its adjacent location, it is conceivable that ST772-MRSA-V in India might have been readily transmitted to Nepal, or it may have been originally endemic in Nepal as well as India.

Although the elastin binding protein (EbpS) gene (*ebpS*) was detected in all the isolates examined by PCR with primers described previously [@bib32], PCR products that were shorter than the expected size (652 bp) were found in four ST22 isolates (data not shown), among which three isolates (NP173, NP177 and NP199; PVL-positive MRSA, PVL-negative MRSA and PVL-positive MSSA respectively) were further analysed for their *ebpS* gene sequences. These *ebpS* genes were revealed to be a variant (*ebpS-v*) with an internal deletion of 180 bp encoding a 60 aa sequence. By BLAST search, sequences similar to *ebpS-v* were identified in strain 71A_S11 (ST22), 93b_S9 and Y12 (ST121) and 6850 (ST50). Alignment of the deduced amino acid sequences of the *ebpS-v* identified in the present study with those of other representative *S. aureus* strains is shown in [Fig. 1](#fig1){ref-type="fig"}. The deleted portion (60 aa) of *ebpS-v* in ST22 Nepalese strains, corresponding to aa 199--258 of EbpS from strain COL, was identical to those found in strains 71A_S11, 93b_S9, Y12 and 6850 (GenBank accession nos. [CP010940](ncbi-n:CP010940){#intref0025}, [CP010952](ncbi-n:CP010952){#intref0030}, [JF706229](ncbi-n:JF706229){#intref0035} and [CP006706](ncbi-n:CP006706){#intref0040}, respectively). Phylogenetic analysis of the *ebpS* from various *S. aureus* strains, including *ebpS-v,* revealed the presence of three major lineages (I, II and III) ([Fig. 2](#fig2){ref-type="fig"}). Lineage II contained the ST22 cluster, which consisted of *ebpS-v* from Nepalese strains and intact *ebpS* in ST22 strains as EMRSA-15. In contrast, *ebpS-v* in ST121 strains clustered in lineage III. Nucleotide sequence identity of intact *ebpS* within the same lineage was more than 98.8%, while it was 95.2--98% between different lineages ([Supplementary Table S2](#appsec1){ref-type="sec"}). *ebpS-v* of ST22 Nepalese strains showed \>99% identity with each other, but slightly lower identity was found in ST121 strains (95.6--95.7%). The variant of *ebpS* with a 180 bp deletion was first reported for isolates from orthopaedic infections in Italy, although their ST was not identified [@bib39]. Thereafter we identified a similar *ebpS* variant (*ebpS-v*) in ST121 MSSA isolates in Myanmar [@bib26] as well as in ST121 isolates in Bangladesh [@bib40] and Japan [@bib41]. The present study elucidated that *ebpS-v* of ST22 and ST121 belong to different lineages, suggesting that the 180 bp deletion event in *ebpS* might have occurred in ST22 *S. aureus* and ST121 *S. aureus* independently.

EbpS, one of the adhesins that binds to host cellular matrix factors involved in biofilm formation, is produced by most MRSA examined so far [@bib41], [@bib42], [@bib43]. EbpS is a cell-surface molecule and mediates binding of bacterial cell to soluble elastin peptides and tropoelastin [@bib44], [@bib45], with its N-terminal region (aa 14--34) a ligand-binding domain exposed on the surface of the cell and two (H1 and H3) among the three putative hydrophobic domains spanning the cell membrane [@bib45]. Although the functional and structural changes caused by the deletion in ST22 isolates are unknown, the N-terminal region must be exposed on the surface of cell for the normal function of *ebpS-v;* accordingly, the H2 region is necessary to span the membrane instead of the deleted H1 region ([Fig. 1](#fig1){ref-type="fig"}, [Supplementary Fig. S1](#appsec1){ref-type="sec"}). In that case, only the form of the cytoplasmic portion of *ebpS-v* may be different from that of EbpS, which may be possible to cause any functional difference.

It was notable in the present study that all the ST22 *S. aureus,* including MRSA and MSSA, harboured *ebpS-v,* while intact *ebpS* was also found in other previously reported ST22 strains including EMRSA-15. In contrast, all the ST121 *S. aureus* analysed to date harboured *ebpS-v* [@bib26], [@bib40], [@bib41]. The ST121 clone is known to be a common cause of skin and soft tissue infection disseminating globally, mostly *mecA* negative but PVL positive, exhibiting higher virulence [@bib46]. Although the association of *ebpS-v* with the enhanced virulence of the ST121 clone is not known, if the presence of *ebpS-v* affects phenotypic trait of ST22 *S. aureus* (e.g. virulence or fitness advantage to environment), it is possible that the proportions of ST22 isolates with *ebpS* and *ebpS-v* may change over time epidemiologically. Further studies thus may be necessary to monitor the prevalence of ST22 *S. aureus* with *ebpS-v.*
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![Alignment of elastin binding protein (EbpS) amino acid sequences from 13 *Staphylococcus aureus* isolates including three ST22 isolates in Nepal. Amino acid numbers based on strain LG251 and CA-347 are shown above sequence. Dot indicates identical amino acid to that of strain 71A_S11 on top; dash denotes gap. LBR near N terminus represents ligand-binding region of EbpS, and H1, H2 and H3 denote three hydrophobic domains. Asterisk indicates position of amino acid deletion detected in lineage II *ebpS* (see [Fig. 2](#fig2){ref-type="fig"}).](gr1){#fig1}

![Phylogenetic dendrogram based on nucleotide sequences of elastin binding protein genes (*ebpS*). Bootstrap values less than 80% are not shown. Three lineages (I, II, III) and ST22 cluster are indicated at right. Closed circle indicates strains with *ebpS-v* (*ebpS* with internal 180 bp deletion). Scale bar = 0.01 substitutions per nucleotide.](gr2){#fig2}

###### 

Frequency of staphylocoagulase (*coa*) genotypes and SCC*mec* types in *Staphylococcus aureus* isolates

  Genotype                                MRSA   MSSA        
  --------------------------------------- ------ ------ ---- ----
  *coa*                                                      
   IIa                                    1      1      2    12
   IIIa                                   2      0      0    1
   IVa                                    1      0      26   0
   Va                                     0      1      5    3
   VIa                                    16     3      6    0
   VIc                                    0      0      0    1
   VIIa                                   2      0      2    2
   VIIb                                   0      0      0    1
   Xa                                     0      0      1    0
   XIa                                    3      2      6    0
  SCC*mec*                                                   
   IV                                     1      1           
   V                                      17     3           
   NI[a](#tbl1fna){ref-type="table-fn"}   7      3           

MRSA, methicillin-resistant *Staphylococcus aureus;* MSSA, methicillin-susceptible *S. aureus;* PVL, Panton-Valentine leukocidin.

Not identified. Ten SCC*mec*-NI strains: two isolates, mec class untypeable (mec-UT)/ccrA2B2; three isolates, mec-UT/ccrC1; three isolates, mec C2/ccr-UT; two isolates, mec-UT/ccr-UT.

###### 

Genetic characteristics and virulence factors in 17 *Staphylococcus aureus* isolates in Nepal

  *mec*A/PVL   Isolate no.   Isolate source   Genotype   Leukocidins, haemolysins[a](#tbl2fna){ref-type="table-fn"}   Enterotoxins[b](#tbl2fnb){ref-type="table-fn"}   Adhesins[a](#tbl2fna){ref-type="table-fn"}^,^[b](#tbl2fnb){ref-type="table-fn"}^,^[c](#tbl2fnc){ref-type="table-fn"}   Other[b](#tbl2fnb){ref-type="table-fn"}                                                                                             
  ------------ ------------- ---------------- ---------- ------------------------------------------------------------ ------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ---------------------------------------------------- ------------------------------------ --------------
  *mec*A       NP154         Urine            V          IIa                                                          III                                              ST1                                                                                                                    *lukE-lukD, hla, hld, hlg2*               *sea, sec, seh, sei, sek, sel, seq*                  *cna, ebpS, fnbA, fib, sdrD, sdrE*   *tst-1*
  *mec*A       NP177         Pus              IV         XIa                                                          I                                                ST22                                                                                                                   *hla, hld*                                *sec, seg, seh, sei, sel, sem, sen, seo, sep*        *cna, ebpS-v, fnbA, sdrD, sdrE*      *chp, tst-1*
  *mec*A       NP18          Urine            V          VIa                                                          II                                               ST772                                                                                                                  *hla, hld, hlg2*                          *sea, sec, seg, sei, sel, sem, sen, seo*             *cna, ebpS, fnbA, fib, sdrD, sdrE*   
  *mec*A/PVL   NP160         Pus              V          VIa                                                          II                                               ST772                                                                                                                  *lukE-lukD, hla, hlg2*                    *sea, sec, seg, seh, sei, sel, sem, sen, seo, sep*   *cna, ebpS, fnbA, fib, sdrD, sdrE*   
  *mec*A/PVL   NP171         Blood            V          VIa                                                          II                                               ST772                                                                                                                  *lukE-lukD, hla, hlg2*                    *sea, sec, seg, seh, sei, sel, sem, sen, seo, sep*   *cna, ebpS, fnbA, fib, sdrD, sdrE*   
  *mec*A/PVL   NP173         Pus              IV         XIa                                                          I                                                ST22                                                                                                                   *lukE-lukD, hla*                          *sec, seg, seh, sei, sel, sem, sen, seo*             *cna, ebpS-v, fnbA, sdrD, sdrE*      *tst-1*
  *mec*A/PVL   NP185         Pus              V          VIa                                                          II                                               ST772                                                                                                                  *lukE-lukD, hla, hlg2*                    *sea, seg, seh, sei, sel, sem, sen, seo, sep*        *cna, ebpS, fnbA, sdrD, sdrE*        
  *mec*A/PVL   NP189         Urine            V          VIa                                                          II                                               ST772                                                                                                                  *lukE-lukD, hla, hlg2*                    *sea, sec, seg, seh, sei, sel, sem, sen, seo, sep*   *cna, ebpS, fnbA, sdrD, sdrE*        
  *mec*A/PVL   NP190         Pus              V          VIIa                                                         III                                              ST1                                                                                                                    *lukE-lukD, hla, hld, hlg2*               *sea, seh, sek, sel, seq*                            *cna, ebpS, fnbA, fib, sdrD, sdrE*   
  *mec*A/PVL   NP27          Pus              V          IIIa                                                         III                                              ST88                                                                                                                   *lukE-lukD, hla, hld, hlg2*               *sed, sek, seq*                                      *ebpS, fnbA, fib, sdrD, sdrE*        
  PVL          NP163         Pus                         IVa                                                          III                                              ST30                                                                                                                   *lukE-lukD, hla*                          *seg, seh, sem, sen, seo, sep*                       *cna, ebpS, fnbA, bbp*               
  PVL          NP169         Pus                         IVa                                                          III                                              ST30                                                                                                                   *hla, hld*                                *seg, sem, sen, seo*                                 *cna, ebpS, fnbA, fib, bbp*          
  PVL          NP172         Pus                         XIa                                                          I                                                ST22                                                                                                                   *lukE-lukD*                               *seg, seh, sei, sel, sem, sen, seo, sep*             *cna, ebpS-v, fnbA, sdrD, sdrE*      
  PVL          NP166         Pus                         VIa                                                          II                                               ST772                                                                                                                  *lukE-lukD, hlg2*                         *sea, sec, seg, seh, sei, sel, sem, sen, seo, sep*   *cna, ebpS, fnbA, sdrD, sdrE*        
  PVL          NP193         Pus                         VIa                                                          II                                               ST772                                                                                                                  *lukE-lukD, hla, hlg2*                    *sea, seg, sei, sel, sem, sen, seo, sep*             *cna, ebpS, fnbA, sdrD, sdrE*        
  PVL          NP199         Urine                       XIa                                                          I                                                ST22                                                                                                                   *lukE-lukD, hla*                          *seg, sei, sem, sen, seo*                            *cna, ebpS-v, sdrD, sdrE*            
  ---          NP195         Pus                         IIa                                                          I                                                ST672                                                                                                                  *lukE-lukD, hla, hld, hlg2*               *seg, sei, sem, seo*                                 *ebpS, fnbA, fib, sdrD, sdrE*        

The following genes were detected in all strains: *hlg, icaA, icaD, eno, fnbB, clfA, clfB, sdrC*.

The following genes were not detected in any strain: *seb, see, sej, ser, ses, set, eta, etb, etd, edin-A, edin-B, lukM, bnp, sak, scn*.

Elastin binding protein gene (*ebpS*) with internal deletion (180 bp).
